Reproducible HILIC Selectivities Unveiled - ACE HILIC-A, B and N

Chromatography

Reproducible HILIC Selectivities Unveiled - ACE HILIC-A, B and N

05 Jul, 2017

Published over 9 years ago. See the latest and most current information on Chromatography.

Three novel HILIC phases were unveiled by Advanced Chromatography Technologies Limited at HPLC 2017, Prague. These proprietary phases enable chromatographers to achieve reproducible and successful HILIC separations via a systematic approach to method development. The three phases comprise of an acidic character phase (ACE HILIC-A), a basic character phase (ACE HILIC-B) and a neutral character phase (ACE HILIC-N); each phase offering alternative selectivity.

  • 3 novel proprietary phases
  • Achieve successful, reproducible HILIC separations
  • A simplified and systematic approach to HILIC method development
  • Compatible with all manufacturers’ HPLC/UHPLC systems
  • Cost effective Method Development kits available
  • Ultra robust up to 1,000 bar (15,000psi)

Competitively priced HILIC Method Development kits are also available, offering all three selectivities for the same price as just a single column. Three particle sizes (1.7, 3 and 5 micron) will be available at launch together with a brochure, application notes, technical knowledge notes and method development guidelines. The range, unveiled at HPLC 2017 Prague, was officially launched on 1st July 2017.

For further information on any ACE product contact us or click here.

Latest News

ILM 51.5 July 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
Measurement to mitigation in the next evolution of emissions monitoring
Explore more Arrow
Pollution Solutions Online
Energy efficiency first: Why shipping must act now while low-GHG fuels scale
Explore more Arrow
Petro Online
Fifty years on, the EU reaffirms its commitment to Seveso-level industrial safety oversight
Explore more Arrow
Chromatography Today
Unlock high-resolution analysis of therapeutic oligonucleotides
Explore more Arrow